The biotechnology R&D intensity in Germany's business sector has shown a significant upward trend from 2013 to 2023. Starting at 1.68 in 2013, it remained relatively steady until 2017, with minor fluctuations. A notable increase began in 2020, where the value surged from 1.72 in 2018 to 2.81. This trajectory continued to accelerate, reaching 5.13 by 2023, marking a 14.26% year-on-year increase over the last two years and a remarkable compound annual growth rate (CAGR) of 24.39% over the past five years. Looking ahead, the forecast suggests a continued rise, anticipating a value of 7.35 by 2028, implying a forecasted five-year CAGR of 5.35%.

Future trends to watch for include:

Continued advancements in biotechnology driving further increases in R&D intensity.
Potential regulatory changes and government support influencing R&D investments.
Emerging biotechnological innovations and breakthroughs facilitating industry growth.
Increased collaboration between academia and the private sector fostering R&D efforts.
Trends in global biotech markets impacting Germany's R&D intensity.